Insight Molecular Diagnostics Inc. (IMDX)
Health Care · molecular diagnostics · NASDAQ
iMDx is disrupting the transplant diagnostics market by enabling hospitals to run their own donor-derived cell-free DNA (dd-cfDNA) tests in-house through a decentralized kitted model.
What Insight Molecular Diagnostics Inc. does
Insight Molecular Diagnostics (iMDx) is a diagnostics technology company focused on decentralizing molecular diagnostic testing, specifically for transplanted organ rejection. It develops kitted tests that allow hospitals and transplant centers to perform testing in-house, moving away from the traditional centralized reference laboratory model. Its flagship technology, GraftAssure, quantifies donor-derived cell-free DNA (dd-cfDNA) to monitor transplanted organ health.
Recent developments
In July 2026, the company reported progress on its FDA review for GraftAssureDx, completing the current phase of substantive review. Additionally, a new favorable Medicare LCD was issued in July 2026, which expands reimbursement for surveillance testing.
From Insight Molecular Diagnostics Inc.'s filing of 2026-08-10.
Themes: transplant diagnostics, decentralized laboratory testing, molecular diagnostics, liquid biopsy, AI / precision medicine (oncology research)
Fundamentals
- Price$3.03 as of 2026-10-20 close
- Market cap$99M as of 2026-08-03 (share count; price 2026-10-20)
- 1-year return-48.6% 2025-10-20 close $5.89 → 2026-10-20 close $3.03
- P/En/a negative earnings
- Net margin-1238.5% FY2025, SEC XBRL
- Gross margin+56.7% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+115.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+61.8% SEC XBRL
- Beta0.91 as of 2026-09-02
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How IMDX compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $239000 | $157000 | -$11M | -$11M | -$0.31 | -$9M† | $779000† |
| Q1 FY2026 2026-03-31 | $32000 | $15000 | -$4M | -$4M | -$0.12 | -$8M | $613000 |
| Q4 FY2025 2025-12-31 | $1M† | $496000† | -$23M† | -$23M† | -$0.74† | -$6M† | $1M† |
| Q3 FY2025 2025-09-30 | $260000 | $139000 | -$11M | -$11M | -$0.34 | -$5M† | $1M† |
| Q2 FY2025 2025-06-30 | $518000 | $338000 | -$10M | -$10M | -$0.30 | -$6M† | $349000† |
| Q1 FY2025 2025-03-31 | $2M | $1M | -$7M | -$7M | -$0.26 | -$6M | $307000 |
| Q4 FY2024 2024-12-31 | $1M† | $595000† | -$34M† | -$34M† | -$2.30† | -$5M† | $214000† |
| Q3 FY2024 2024-09-30 | $115000 | $50000 | -$14M | -$13M | -$0.98 | -$6M† | $87000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$18M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Insight Molecular Diagnostics Inc. looks technically
Insight Molecular Diagnostics Inc. (IMDX) is trading 38.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 118 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago. It is 64.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 38.3% below its 200-day average, the long-term trend line — a long-term downtrend | -38.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.82 | $3.82 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.91 | $4.91 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.7566. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 118 trading days ago — a "death cross", a bearish long-term signal | 118 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with sellers in control | 44.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 40.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($2.75 to $3.76) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 27.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.51 | $8.51 |
|---|---|---|
| From the 52-week high | it is 64.4% below its 52-week high (its highest price of the past year) | -64.4% |
| Above the 52-week low | it is 25.2% above its 52-week low (its lowest price of the past year) | +25.2% |
| Below the 52-week high | it is 64.4% below its highest point of the past year | 64.4% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $204.80 (set on 2016-01-05) | $204.80 |
| Given back of the 52-week move | over the past year its closes ranged ($2.55 to $8.48), and it has recovered only a small part of its fall from last year’s high — 8% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.21 to $6.40. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 8.1% |
| From the all-time high | it is 98.5% below its all-time high | -98.5% |
| Nearest price level | it is sitting right on a resistance level at $3.04 — a price it turned at three times since 2024-11-12, most recently on 2026-09-29. Since 2024-10-21 it has 6 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.3% |
| All-time low | its lowest closing price on record is $1.92 (set on 2025-01-22) | $1.92 |
| Above the all-time low | it is 57.6% above its all-time low | +57.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3571 between its high and its low — about 11.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3571 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.68 and $4.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.68 – $3.35 – $4.01 |
| Typical daily range (% of price) | its price moves about 11.8% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 11.8% |
| Stretch from the 200-day average | it is trading 5.3 daily ranges below its 200-day average price (38.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.03× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 2.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +2.4% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close today and has not traded back through the level it left behind at 2.89 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.6% gap down opened on 2026-09-28 has been "filled" 16 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 16 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 25.2 percentage points (the stock lost 24.3% while the market gained 1.0%) | -25.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.0 percentage points (the stock lost 37.4% while the market gained 3.6%) | -41.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 32.6 percentage points (the stock lost 24.1% while the market gained 8.5%) | -32.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 63.1 percentage points (the stock lost 48.6% while the market gained 14.6%) | -63.1% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 27% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 21.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -26.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.42 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -31.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.74 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -18.9% |
Price levels it has turned at before
IMDX last closed at $3.03 on 2026-10-20. Since 2024-10-21 it has turned at 6 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.04 | Resistance | 0.3% above the last close | turned there three times · 2024-11-12 to 2026-09-29 |
| $2.63 | Support | 13.2% below the last close | turned there four times · 2025-04-07 to 2026-04-10 |
| $3.49 | Resistance | 15.1% above the last close | turned there three times · 2025-04-25 to 2026-09-16 |
| $2.56 | Support | 15.6% below the last close | turned there three times · 2024-12-09 to 2025-06-12 |
| $3.57 | Resistance | 17.9% above the last close | turned there twice · 2025-09-16 to 2026-08-13 |
| $2.41 | Support | 20.4% below the last close | turned there twice · 2025-01-31 to 2025-09-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.76.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.83 and $2.57 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.76.
This reading has stood for 6 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$8.25 range $4.00 – $12.00; median $8.50
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMDX
- Consensus EPS estimate-$0.22 next reporting period, as of 2026-10-16
- Estimate change, 30 days$0.00 from -$0.22, on 2026-09-11, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on FDA regulatory authorization for clinical commercialization of kitted products.","Dependence on favorable Medicare reimbursement coverage (LCDs) and evolving third-party payer policies.","History of losses and dependence on external financing to fund operations."]
What changed in the latest 10-Q
AI-assisted comparison of IMDX's 10-Q filed 2026-08-10 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-10) states that since the March 2026 FDA submission, the company has had meaningful and productive dialogue with the FDA as it works with reviewers to obtain marketing authorization to market and sell GraftAssureDx.
- Newer filing (2026-08-10) adds that from time to time, the company may evaluate strategic alternatives to commercializing and further developing its oncology assets, including but not limited to a divestiture or licensing of such assets, which it may pursue if determined to be in the best interests of shareholders and customers.
- Newer filing (2026-08-10) adds that the company may not be able to accurately estimate the timing of any such strategic alternative, valuation or purchase price, or whether economic or other market conditions will impact the timing, price or market interest.
- Newer filing (2026-08-10) adds that there is no guarantee the company is able to negotiate terms of a strategic acceptable to the Company, successfully complete a transaction at all, or that the results of such strategic alternative will be successful.
- Newer filing (2026-08-10) changes the description of initial targeted customer institutions to include 'including large reference laboratories.'
- Removed:
- Older filing (2026-05-13) stated that in May 2025, the company sold its first GraftAssureIQ kits to a research laboratory customer, with a cross-reference to Note 2, 'Revenue Recognition – Kitted Products.'
- Older filing (2026-05-13) included a paragraph describing a Specimen Collection Agreement with a national reference lab provider entered into on February 20, 2026, pursuant to which the lab provider would provide specimen collection-related services for GraftAssureCore testing.
- Older filing (2026-05-13) included concluding sentences about the company believing the experience of its team with diverse technologies through Laboratory Services activities, strong scientific integrity, innovation mentality, flexibility in operations and regulatory strategy will drive success, differentiate from competition, and are foundational to the future, including that the company is focusing on executing technology priorities which have evolved to reflect operations and strategy.
- Reworded:
- Newer filing (2026-08-10) covers the three and six months ended June 30, 2026 and 2025, while the older filing (2026-05-13) covered the three months ended March 31, 2026 and 2025.
- Newer filing (2026-08-10) describes the company's current intellectual property portfolio as comprising 'organ transplant testing,' while the older filing (2026-05-13) described it as comprising 'organ transplant.'
- Newer filing (2026-08-10) changes the cross-reference for Kitted Products revenue information from 'see Note 2, "Revenue Recognition – Kitted Products,"' to 'see Note 2, "Revenue Recognition,"' reflecting a different note reference label.
- Notes:
- The newer filing text appears truncated at the end (ending mid-sentence: 'through our Laborat'), so changes occurring after that point cannot be assessed.
- This comparison is limited to the MD&A overview section text provided; other MD&A subsections such as Results of Operations or Liquidity and Capital Resources are not included in the provided excerpts.
Risk Factors
- Added:
- Newer filing (2026-08-10) includes extensive new disclosure under Risk Factors about third-party payer coverage and Medicare/CMS reimbursement, including MACs, the MolDx Program, and Palmetto GBA.
- Newer filing (2026-08-10) states: 'Our primary near-term strategic market is organ transplant. We received a positive coverage decision from MolDx for GraftAssureCore (Kidney) in August of 2023, and it became commercially available for ordering in January 2024. In December 2024, we confirmed Medicare reimbursement for also monitoring certain high-risk patients, that is, those with newly developed donor-specific antibodies.'
- Newer filing (2026-08-10) states: 'On July 16, 2026, MolDX revised its foundational LCD, "MolDX Molecular Testing for Solid Organ Allograft Rejection" (L40062)... the revised LCD supports a higher testing frequency through the allowance of surveillance coverage in addition to the already-covered for-cause testing.'
- Newer filing (2026-08-10) includes additional paragraph on risks if tests are not reimbursed or lose Medicare reimbursement, and additional language on CMS/local contractor decisions reducing or denying coverage.
- Newer filing (2026-08-10) includes additional paragraph on coverage policies and reimbursement rates potentially changing at any time.
- Reworded:
- Older filing (2026-05-13) stated: 'There have been no material changes from the risk factors disclosed in our most recent Annual Report on Form 10-K.' Newer filing (2026-08-10) changed this to: 'Other than as noted below, there have been no material changes from the risk factors disclosed in our most recent Annual Report on Form 10-K.'
- Notes:
- The user requested comparison of the 'Risk Factors' section only; the provided texts also include portions of Items 2-6 and exhibits, which were not analyzed.
- The newer filing text may be truncated before the exhibits section end.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-162 buys ($913134) · 0 sells — 1 buying insider
Most recent open-market transaction: 2026-04-27. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IMDX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
2 institutional 13F filers reported holding IMDX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 2
- Reported shares held 242,645
- Reported value $1,431,606
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IMDX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IMDX had 973,029 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
IMDX had 2.97% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.91 days to cover at the same settlement.
- Reported short interest (shares) 973,029
- Short interest (% of shares outstanding) 2.97%
- Prior settlement (shares) 992,474
- Reported change -1.96%
- Days to cover (reported) 2.91
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CareDx (CDNA)
- Natera (NTRA)
- Eurofins Scientific (ERFSF)
- Quest Diagnostics (DGX)
- Laboratory Corporation of America (LH)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IMDX vs…
Insight Molecular Diagnostics Inc. is found in…
Frequently asked questions
What does Insight Molecular Diagnostics Inc. (IMDX) do?
Insight Molecular Diagnostics (iMDx) is a diagnostics technology company focused on decentralizing molecular diagnostic testing, specifically for transplanted organ rejection. It develops kitted tests that allow hospitals and transplant centers to perform testing in-house, moving away from the traditional centralized reference laboratory model. Its flagship technology, GraftAssure, quantifies donor-derived cell-free DNA (dd-cfDNA) to monitor transplanted organ health.
What sector is Insight Molecular Diagnostics Inc. (IMDX) in?
Insight Molecular Diagnostics Inc. (IMDX) is classified in the Health Care sector. Its industry is molecular diagnostics. It trades on NASDAQ.
Who are Insight Molecular Diagnostics Inc.'s (IMDX) competitors?
Notable peers of Insight Molecular Diagnostics Inc. (IMDX) include CareDx, Natera, Eurofins Scientific, Quest Diagnostics and Laboratory Corporation of America. This peer set is informational only — not financial advice.
Is Insight Molecular Diagnostics Inc. (IMDX) overbought or oversold right now?
Insight Molecular Diagnostics Inc. (IMDX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMDX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.